Legal Reasons and/or Threats
- Long-term maintenance of clinical remission with reduced dosing frequency of adalimumab in patients with moderate to severe Crohn’s disease1/24/2022 0:00
- Efficacy and safety of beclomethasone dipropionate gastro-resistant, prolonged release tablet in mild to moderate ulcerative colitis: The Beta study1/24/2022 0:00
- Genetic mutations of thiopurine-methyltransferase (TPMT) in inflammatory bowel disease patients with normal TPMT phenotype and thiopurine-induced myelotoxicity1/24/2022 0:00
- Preclinical and toxicological assessments of the novel orally bioavailable PPAR ligand GED-0507 34-Levo for the treatment of inflammatory bowel disease1/24/2022 0:00
- Taking Swedish oat bran is superior to a usual diet in maintaining ulcerative colitis patients in remission Randomized placebo-controlled trial1/24/2022 0:00
- Efficacy of adalimumab in the treatment of ulcerative colitis1/24/2022 0:00
- Mycophenolate mofetil in inflammatory bowel diseases: A promise unfulfilled?1/24/2022 0:00
- Intravenous iron reduces platelet counts in IBD-associated thrombocytosis. A prospective, randomized, placebo-controlled trial1/24/2022 0:00
- Do we over estimate the risks of capsule endoscopy in suspected or established small bowel Crohn’s disease? A comparison with completion rates and complications observed in the setting of obscure GI bleeding1/24/2022 0:00
- Certolizumab pegol is effective at maintaining response and remission in patients with fistulizing Crohn’s disease: 3-year results from the PRECiSE 3 study1/24/2022 0:00
- Patients with Crohn’s disease treated with certolizumab pegol experienced long-term remission regardless of prior TNF-a inhibitor exposure (PRECiSE 4 study)1/24/2022 0:00
- Anaemia is more common but apparently less often treated in children than adolescents and adults with IBD1/24/2022 0:00
- Limited intra-individual variability in hypoxanthine-guanine phosphoribosyl transferase, thiopurine S-methyl transferase and xanthine oxidase activity in IBD patients during 6-thioguanine therapy1/24/2022 0:00
- Patient undergoing colectomy because of ulcerative colitis had a very high rate of surgical complications in clinical practice conditions1/24/2022 0:00
- Anti TNF therapy in elderly people in IBD: A multicentre survey1/24/2022 0:00
- Mucosal healing in ulcerative colitis patients treated with azathioprine and its influence on quality of life1/24/2022 0:00
- Atherosclerosis in patients with infammatory bowel diseases: Evaluation of several candidate factors for early detection1/24/2022 0:00
- Thiopurine-induced myelotoxicity in inflammatory bowel disease (IBD): A multicenter study1/24/2022 0:00
- Effectiveness of infliximab after adalimumab failure in Crohn’s disease1/24/2022 0:00
- Effect of anti-TNF alpha treatment on short-term post-operative complications in patients with inflammatory bowel disease: An Italian single center experience1/24/2022 0:00
- Early response to combined oral and topical mesalazine (PENTASA®) for ulcerative colitis: Post-hoc analysis of efficacy at two weeks in the PINCE trial1/24/2022 0:00
- Smokers with inflammatory bowel disease have low nicotine dependence1/24/2022 0:00
- Infliximab in steroid-refractory pediatric ulcerative colitis: Predictors of response in a prospective multicenter study1/24/2022 0:00
- Audit of prevention of opportunistic infections in immunosuppressed patients with IBD: How close are we to ECCO guidelines?1/24/2022 0:00
- Azathioprine and smoking habits are the only predictors of severe endoscopic postoperative recurrence in Crohn’s disease: Results of a prospective study1/24/2022 0:00
- Impact of medical treatments on the clinical course of inflammatory bowel diseases (IBD): Data from a French regional survey1/24/2022 0:00
- Skin complications during therapy with anti-TNFa preparations: Experience of a single centre1/24/2022 0:00
- Long-term durability of response to adalimumab treatment in Crohn’s disease1/24/2022 0:00
- Effectiveness of adalimumab in the treatment of extraintestinal manifestations of Crohn’s disease1/24/2022 0:00
- Patient response to anti-TNF dose escalation in Crohn’s disease using health claims data1/24/2022 0:00
- Mesenchymal stem cells transplantation decreases relapse development risk in patients with ulcerative colitis1/24/2022 0:00
- Recommendations from available standards on organizational aspects for the management of inflammatory bowel disease by specialist nurses1/24/2022 0:00
- Predicting outcome of infliximab treatment in Crohn’s disease1/24/2022 0:00
- Is methotrexate for inflammatory bowel diseases underused in clinical practice?1/24/2022 0:00
- Long-term results with mesalazine therapy in patients persistent with therapy at outset1/24/2022 0:00
- Local infliximab treatment in ileocolonic anastomotic Crohn’s disease recurrence: Efficacy at 12 months follow-up1/24/2022 0:00
- The benefit of a tailored patient preference intervention in adherence to 5-ASA medication in ulcerative colitis: Results from a randomised controlled trial1/24/2022 0:00
- Endoscopic outcome of medium term adalimumab therapy in patients with Crohn’s disease. National data from Hungary1/24/2022 0:00
- Mucosal healing with methotrexate in Crohn’s disease: A prospective comparative study with azathioprine and infliximab1/24/2022 0:00
- UK inflammatory bowel disease audit: IBD nurse correlations between 2006 and 20081/24/2022 0:00
- A multidisciplinary virtual biologic clinic: Is it worthwhile?1/24/2022 0:00
- Adalimumab versus Infliximab clinical comparision: Longitudinal study1/24/2022 0:00
- Efficacy and safety of chronic hepatitis C treatment with pegylated interferon alpha 2a/b and ribavirin in patients with inflammatory bowel disease1/24/2022 0:00
- Early post-operative endoscopic recurrence in Crohn’s disease in an Italian multicentric cohort1/24/2022 0:00
- Long term efficacy of granulocyte-monocyte-apheresis in ulcerative colitis. The Italian Registry of Therapeutic Apheresis1/24/2022 0:00
- Evaluation of potential correlations between serum adalimumab concentration and remission in patients with Crohn’s disease in CLASSIC I and II1/24/2022 0:00
- Fecal calprotectin may differentiate between IBS and IBD symptomes in IBD patients1/24/2022 0:00
- Paradoxical effect of IL13 blockage in inflamed colon mucosa of ulcerative colitis patients1/24/2022 0:00
- Emerging safety profile of vedolizumab: A novel, selective integrin inhibitor for treatment of IBD1/24/2022 0:00
- Certolizumab pegol demonstrates efficacy in maintaining response and remission in patients with active Crohn’s disease regardless of their immunosuppressant treatment status at entry to the PRECiSE 2 study1/24/2022 0:00